These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 20852268

  • 21. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
    Codoñer FM, Pou C, Thielen A, García F, Delgado R, Dalmau D, Santos JR, Buzón MJ, Martínez-Picado J, Alvarez-Tejado M, Clotet B, Ruiz L, Paredes R.
    Antiviral Res; 2010 Dec; 88(3):281-6. PubMed ID: 20883724
    [Abstract] [Full Text] [Related]

  • 22. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
    Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R.
    Virology; 2010 Jul 05; 402(2):338-46. PubMed ID: 20421122
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of raltegravir in HIV/AIDS.
    Chaudhary MA, Elbasha EH, Kumar RN, Nathanson EC.
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec 05; 11(6):627-39. PubMed ID: 22098278
    [Abstract] [Full Text] [Related]

  • 24. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
    Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Gonzalez Paz O, Hazuda DJ, Jones P, Kinzel O, Laufer R, Monteagudo E, Muraglia E, Nizi E, Orvieto F, Pace P, Pescatore G, Scarpelli R, Stillmock K, Witmer MV, Rowley M.
    J Med Chem; 2008 Sep 25; 51(18):5843-55. PubMed ID: 18763751
    [Abstract] [Full Text] [Related]

  • 25. [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
    Delaugerre C.
    Med Mal Infect; 2010 Sep 25; 40 Suppl 1():S1-10. PubMed ID: 20800182
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY, BENCHMRK Study Teams.
    N Engl J Med; 2008 Jul 24; 359(4):355-65. PubMed ID: 18650513
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Resistance to novel drug classes.
    Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V.
    Curr Opin HIV AIDS; 2009 Nov 24; 4(6):531-7. PubMed ID: 20048722
    [Abstract] [Full Text] [Related]

  • 32. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
    Buzón MJ, Dalmau J, Puertas MC, Puig J, Clotet B, Martinez-Picado J.
    AIDS; 2010 Jan 02; 24(1):17-25. PubMed ID: 19770695
    [Abstract] [Full Text] [Related]

  • 33. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.
    Canducci F, Ceresola ER, Boeri E, Spagnuolo V, Cossarini F, Castagna A, Lazzarin A, Clementi M.
    J Infect Dis; 2011 Dec 01; 204(11):1811-5. PubMed ID: 21984737
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
    Mangiafico L, Perja M, Fusco F, Riva S, Mago D, Gringeri A.
    Haemophilia; 2012 Jan 01; 18(1):108-11. PubMed ID: 21762404
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.
    McColl DJ, Chen X.
    Antiviral Res; 2010 Jan 01; 85(1):101-18. PubMed ID: 19925830
    [Abstract] [Full Text] [Related]

  • 38. Emerging patterns and implications of HIV-1 integrase inhibitor resistance.
    Geretti AM, Armenia D, Ceccherini-Silberstein F.
    Curr Opin Infect Dis; 2012 Dec 01; 25(6):677-86. PubMed ID: 23086187
    [Abstract] [Full Text] [Related]

  • 39. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
    Fun A, Van Baelen K, van Lelyveld SF, Schipper PJ, Stuyver LJ, Wensing AM, Nijhuis M.
    J Antimicrob Chemother; 2010 Nov 01; 65(11):2300-4. PubMed ID: 20736234
    [Abstract] [Full Text] [Related]

  • 40. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
    Rathbun RC, Lockhart SM, Miller MM, Liedtke MD.
    Ann Pharmacother; 2014 Mar 01; 48(3):395-403. PubMed ID: 24259658
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.